Injection device
Latest NOVARTIS AG Patents:
- NMDA receptor modulators and uses thereof
- Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors
- CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
- CD19 and CD22 chimeric antigen receptors and uses thereof
- ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
Description
Portions of the design shown in broken lines are visible through transparent components of the injection device and form no part of the design as claimed.
Claims
The ornamental design for an injection device, as shown and described.
Referenced Cited
U.S. Patent Documents
7651512 | January 26, 2010 | Chelak |
D827127 | August 28, 2018 | Donnelly |
D830539 | October 9, 2018 | Boyaval |
D841155 | February 19, 2019 | McMenamin |
D841156 | February 19, 2019 | McMenamin |
D862690 | October 8, 2019 | Jansen |
D869647 | December 10, 2019 | Dorsey |
D888942 | June 30, 2020 | Cannamela |
D897184 | September 29, 2020 | Perkins, Jr. |
D897185 | September 29, 2020 | Perkins, Jr. |
D903856 | December 1, 2020 | Nicholas |
D910836 | February 16, 2021 | Sandberg |
D910837 | February 16, 2021 | Ono |
Patent History
Patent number: D928940
Type: Grant
Filed: Dec 12, 2019
Date of Patent: Aug 24, 2021
Assignee: NOVARTIS AG (Basel)
Inventors: Neil Cammish (Manchester), John Palmer-Felgate (Horsham), Mark Horlock (Warrington), Congyi Huang (Klagenfurt), Adrian Von Muralt (Basel)
Primary Examiner: David G Muller
Application Number: 29/716,809
Type: Grant
Filed: Dec 12, 2019
Date of Patent: Aug 24, 2021
Assignee: NOVARTIS AG (Basel)
Inventors: Neil Cammish (Manchester), John Palmer-Felgate (Horsham), Mark Horlock (Warrington), Congyi Huang (Klagenfurt), Adrian Von Muralt (Basel)
Primary Examiner: David G Muller
Application Number: 29/716,809
Classifications
Current U.S. Class:
Hand Actuated Flow Control (e.g., Lever, Button, Etc.) (D24/113)